pharmaphorum July 21, 2021
Phil Taylor

Think of the R&D dollars that could be saved if artificial intelligence (AI) modelling could tell you at an early stage whether a drug was likely to succeed in clinical trials, and ultimately reach the market.

In 2019, a team at Massachusetts Institute of Technology (MIT) in the US came up with just such a model, and found that it was able to perform “better than random” at predicting the outcome of a clinical trial or development programme.

Professor Andrew Lo, director of the MIT Computer Science and Artificial Intelligence Laboratory (CSAIL) worked on the initial machine learning (ML) model, which used drug development and clinical trial data harvested from the Informa Pharma Intelligence database, including drug compound characteristics, clinical...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Technology
Amazon invests another $2.75B in Anthropic — reportedly ‘largest’ in company history
Policy at global conference focuses on three central issues
How Remote Patient Monitoring and AI Personalize Care
How Nebraska Medicine used AI to reduce first-year nurse turnover by nearly 50%
Social Isolation Linked to Being Older Than Biological Age, Greater Mortality

Share This Article